Company intelligence / Profile preview

Neuraly

Baltimore, Maryland, USAneuralymed.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Completed Phase 2 trial of NLY01 in Parkinson's disease with topline results announced in March 2023. Also received FDA clearance for Phase 2B trial of NLY01 in Alzheimer's disease patients.

Therapeutic areas: Neurology
Modalities: GLP-1R agonistssmall moleculesc-Abl inhibitors
Industry: Biotech

Drug pipeline

4 assets

pegsebrenatide

3 more assets in the full pipeline.

Request access →

Partnerships

Enigma Biomedical USA1st Biotherapeutics Inc.

Beyond the preview

Go deeper on Neuraly.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuraly.

Explore the full profile